These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25370126)

  • 1. Anandamide is involved in appetite-related amygdala hyperactivations in schizophrenia patients treated with olanzapine: a functional magnetic resonance imaging study.
    Potvin S; Lungu OV; Stip E
    J Clin Psychopharmacol; 2015 Feb; 35(1):82-3. PubMed ID: 25370126
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of anandamide with altered binocular depth inversion illusion in schizophrenia.
    Reuter AR; Bumb JM; Mueller JK; Rohleder C; Pahlisch F; Hanke F; Arens E; Leweke FM; Koethe D; Schwarz E
    World J Biol Psychiatry; 2017 Sep; 18(6):483-488. PubMed ID: 27734750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients.
    Smith RC; Rachakonda S; Dwivedi S; Davis JM
    Psychiatry Res; 2012 Oct; 199(3):159-63. PubMed ID: 22475524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment.
    Stip E; Lungu OV; Anselmo K; Letourneau G; Mendrek A; Stip B; Lipp O; Lalonde P; Bentaleb LA
    Transl Psychiatry; 2012 Jun; 2(6):e128. PubMed ID: 22714121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anandamide dysfunction in prodromal and established psychosis.
    Leweke FM
    Curr Pharm Des; 2012; 18(32):5188-93. PubMed ID: 22716147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential role of appetite in predicting weight changes during treatment with olanzapine.
    Case M; Treuer T; Karagianis J; Hoffmann VP
    BMC Psychiatry; 2010 Sep; 10():72. PubMed ID: 20840778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is olanzapine a brain-sparing medication?
    Joober R; Schmitz N; Malla A; Sengupta S; Karma S
    Arch Gen Psychiatry; 2006 Nov; 63(11):1292. PubMed ID: 17088510
    [No Abstract]   [Full Text] [Related]  

  • 8. Olanzapine increases plasma ghrelin level in patients with schizophrenia.
    Murashita M; Kusumi I; Inoue T; Takahashi Y; Hosoda H; Kangawa K; Koyama T
    Psychoneuroendocrinology; 2005 Jan; 30(1):106-10. PubMed ID: 15358448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications.
    Lasser RA; Mao L; Gharabawi G
    Schizophr Res; 2004 Feb; 66(2-3):163-7. PubMed ID: 15061249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.
    Chen CH; Huang MC; Lu ML
    J Clin Psychopharmacol; 2007 Oct; 27(5):516-7. PubMed ID: 17873689
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.
    Leweke FM; Piomelli D; Pahlisch F; Muhl D; Gerth CW; Hoyer C; Klosterkötter J; Hellmich M; Koethe D
    Transl Psychiatry; 2012 Mar; 2(3):e94. PubMed ID: 22832859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma anandamide concentration and pregnancy outcome in women with threatened miscarriage.
    Habayeb OM; Taylor AH; Finney M; Evans MD; Konje JC
    JAMA; 2008 Mar; 299(10):1135-6. PubMed ID: 18334688
    [No Abstract]   [Full Text] [Related]  

  • 14. Anandamide as a marker of human disease.
    Maccarrone M
    JAMA; 2008 Jul; 300(3):281-2; author reply 282. PubMed ID: 18632539
    [No Abstract]   [Full Text] [Related]  

  • 15. Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy.
    Potvin S; Kouassi E; Lipp O; Bouchard RH; Roy MA; Demers MF; Gendron A; Astarita G; Piomelli D; Stip E
    J Psychopharmacol; 2008 May; 22(3):262-9. PubMed ID: 18308802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial abnormalities of endocannabinoid signaling in schizophrenia.
    Koethe D; Pahlisch F; Hellmich M; Rohleder C; Mueller JK; Meyer-Lindenberg A; Torrey EF; Piomelli D; Leweke FM
    World J Biol Psychiatry; 2019 Feb; 20(2):117-125. PubMed ID: 29521179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.
    Baptista T; Martinez M; Lacruz A; Arellano A; Mendoza S; Beaulieu S; Hernández L; Contreras Q; Galeazzi T; Vargas D
    Schizophr Res; 2007 Jan; 89(1-3):350-2. PubMed ID: 17029751
    [No Abstract]   [Full Text] [Related]  

  • 18. Trajectories of agouti-related protein and leptin levels during antipsychotic-associated weight gain in patients with schizophrenia.
    Ehrlich S; Leopold K; Merle JV; Theophil I; Haag W; Lautenschlager M; Schaefer M
    J Clin Psychopharmacol; 2012 Dec; 32(6):767-72. PubMed ID: 23131879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of olanzapine on 31P MRS metabolic markers in schizophrenia.
    Nenadic I; Dietzek M; Langbein K; Rzanny R; Gussew A; Reichenbach JR; Sauer H; Smesny S
    Hum Psychopharmacol; 2013 Jan; 28(1):91-3. PubMed ID: 23225665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.